3 Absurdly Cheap Stocks You Can Buy for Less than $100 Right Now

Core Insights - The article highlights three undervalued stocks: Novo Nordisk, Target, and Pfizer, which are trading below $100 per share and have strong fundamentals despite recent poor performance [2]. Novo Nordisk - Novo Nordisk is a major player in the GLP-1 drug market, with key products like Wegovy and Ozempic generating billions in revenue [4]. - The stock price has dropped nearly 32% this year, trading at just under $59, following a lowered fiscal year guidance due to slower growth and competition from knockoff drugs [5][6]. - Despite the recent downturn, the company has significant growth potential, particularly with Wegovy's expansion into new markets and promising results from its oral version [6][7]. Target - Target's stock has decreased almost 35% this year, currently trading around $88, with revenue for the first half of the year totaling $49.1 billion, down 2% year-over-year [9]. - The company faces challenges due to reduced consumer discretionary spending and economic conditions, but it aims to increase sales by $15 billion by the end of the decade through online marketplace growth and same-day delivery [10][11]. - Target generated nearly $3 billion in free cash flow over the past 12 months and trades at a low P/E multiple of slightly over 10, indicating it may be an undervalued stock worth considering [11]. Pfizer - Pfizer's stock is trading just over $24, down 9% since January and more than 50% from its 2021 highs, primarily due to concerns over future growth and multiple patent cliffs [12][13]. - Revenue for the first half of 2025 has only risen by 1% to $28.4 billion, raising concerns among growth investors [13]. - The company is expanding its pipeline through acquisitions, including a planned purchase of GLP-1 drugmaker Metsera for up to $7.3 billion, which could enhance its position in the obesity market [14][15]. - Pfizer generates substantial free cash flow of $12.4 billion over the past 12 months, providing financial flexibility for acquisitions and potential growth opportunities [15][16].